Literature DB >> 19439349

IL-22-producing "T22" T cells account for upregulated IL-22 in atopic dermatitis despite reduced IL-17-producing TH17 T cells.

Kristine E Nograles1, Lisa C Zaba, Avner Shemer, Judilyn Fuentes-Duculan, Irma Cardinale, Toyoko Kikuchi, Michal Ramon, Reuven Bergman, James G Krueger, Emma Guttman-Yassky.   

Abstract

BACKGROUND: Psoriasis and atopic dermatitis (AD) are common inflammatory skin diseases. An upregulated TH17/IL-23 pathway was demonstrated in psoriasis. Although potential involvement of TH17 T cells in AD was suggested during acute disease, the role of these cells in chronic AD remains unclear.
OBJECTIVE: To examine differences in IL-23/TH17 signal between these diseases and establish relative frequencies of T-cell subsets in AD.
METHODS: Skin biopsies and peripheral blood were collected from patients with chronic AD (n = 12) and psoriasis (n = 13). Relative frequencies of CD4+ and CD8+ T-cell subsets within these 2 compartments were examined by intracellular cytokine staining and flow cytometry.
RESULTS: In peripheral blood, no significant difference was found in percentages of different T-cell subsets between these diseases. In contrast, psoriatic skin had significantly increased frequencies of TH1 and TH17 T cells compared with AD, whereas TH2 T cells were significantly elevated in AD. Distinct IL-22-producing CD4+ and CD8+ T-cell populations were significantly increased in AD skin compared with psoriasis. IL-22+CD8+ T-cell frequency correlated with AD disease severity.
CONCLUSION: Our data established that T cells could independently express IL-22 even with low expression levels of IL-17. This argues for a functional specialization of T cells such that "T17" and "T22" T-cells may drive different features of epidermal pathology in inflammatory skin diseases, including induction of antimicrobial peptides for "T17" T cells and epidermal hyperplasia for "T22" T-cells. Given the clinical correlation with disease severity, further characterization of "T22" T cells is warranted, and may have future therapeutic implications.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19439349      PMCID: PMC2874584          DOI: 10.1016/j.jaci.2009.03.041

Source DB:  PubMed          Journal:  J Allergy Clin Immunol        ISSN: 0091-6749            Impact factor:   10.793


  27 in total

1.  The effects of IL-20 subfamily cytokines on reconstituted human epidermis suggest potential roles in cutaneous innate defense and pathogenic adaptive immunity in psoriasis.

Authors:  Susan M Sa; Patricia A Valdez; Jianfeng Wu; Kenneth Jung; Fiona Zhong; Linda Hall; Ian Kasman; Jane Winer; Zora Modrusan; Dimitry M Danilenko; Wenjun Ouyang
Journal:  J Immunol       Date:  2007-02-15       Impact factor: 5.422

2.  Interleukin-22, a T(H)17 cytokine, mediates IL-23-induced dermal inflammation and acanthosis.

Authors:  Yan Zheng; Dimitry M Danilenko; Patricia Valdez; Ian Kasman; Jeffrey Eastham-Anderson; Jianfeng Wu; Wenjun Ouyang
Journal:  Nature       Date:  2006-12-24       Impact factor: 49.962

3.  High expression levels of keratinocyte antimicrobial proteins in psoriasis compared with atopic dermatitis.

Authors:  Gys J de Jongh; Patrick L J M Zeeuwen; Martina Kucharekova; Rolph Pfundt; Pieter G van der Valk; Willeke Blokx; Aynur Dogan; Pieter S Hiemstra; Peter C van de Kerkhof; Joost Schalkwijk
Journal:  J Invest Dermatol       Date:  2005-12       Impact factor: 8.551

4.  IL-4 gene therapy for collagen arthritis suppresses synovial IL-17 and osteoprotegerin ligand and prevents bone erosion.

Authors:  E Lubberts; L A Joosten; M Chabaud; L van Den Bersselaar; B Oppers; C J Coenen-De Roo; C D Richards; P Miossec; W B van Den Berg
Journal:  J Clin Invest       Date:  2000-06       Impact factor: 14.808

5.  IL-22 inhibits epidermal differentiation and induces proinflammatory gene expression and migration of human keratinocytes.

Authors:  Katia Boniface; François-Xavier Bernard; Martine Garcia; Austin L Gurney; Jean-Claude Lecron; Franck Morel
Journal:  J Immunol       Date:  2005-03-15       Impact factor: 5.422

6.  Major differences in inflammatory dendritic cells and their products distinguish atopic dermatitis from psoriasis.

Authors:  Emma Guttman-Yassky; Michelle A Lowes; Judilyn Fuentes-Duculan; Julia Whynot; Inna Novitskaya; Irma Cardinale; Asifa Haider; Artemis Khatcherian; John A Carucci; Reuven Bergman; James G Krueger
Journal:  J Allergy Clin Immunol       Date:  2007-05       Impact factor: 10.793

7.  Possible pathogenic role of Th17 cells for atopic dermatitis.

Authors:  Chizuko Koga; Kenji Kabashima; Noriko Shiraishi; Miwa Kobayashi; Yoshiki Tokura
Journal:  J Invest Dermatol       Date:  2008-04-24       Impact factor: 8.551

8.  Skin-infiltrating CD8+ T cells initiate atopic dermatitis lesions.

Authors:  Ana Hennino; Marc Vocanson; Yann Toussaint; Karen Rodet; Josette Benetière; Anne-Marie Schmitt; Marie-Françoise Aries; Frédéric Bérard; Aurore Rozières; Jean-François Nicolas
Journal:  J Immunol       Date:  2007-05-01       Impact factor: 5.422

9.  Interleukin (IL)-22 and IL-17 are coexpressed by Th17 cells and cooperatively enhance expression of antimicrobial peptides.

Authors:  Spencer C Liang; Xiang-Yang Tan; Deborah P Luxenberg; Riyez Karim; Kyriaki Dunussi-Joannopoulos; Mary Collins; Lynette A Fouser
Journal:  J Exp Med       Date:  2006-09-18       Impact factor: 14.307

10.  Cytokine modulation of atopic dermatitis filaggrin skin expression.

Authors:  Michael D Howell; Byung Eui Kim; Peisong Gao; Audrey V Grant; Mark Boguniewicz; Anna Debenedetto; Lynda Schneider; Lisa A Beck; Kathleen C Barnes; Donald Y M Leung
Journal:  J Allergy Clin Immunol       Date:  2007-05-23       Impact factor: 10.793

View more
  189 in total

1.  Functionally distinct subsets of human FOXP3+ Treg cells that phenotypically mirror effector Th cells.

Authors:  Thomas Duhen; Rebekka Duhen; Antonio Lanzavecchia; Federica Sallusto; Daniel J Campbell
Journal:  Blood       Date:  2012-03-21       Impact factor: 22.113

Review 2.  New insights in the immunologic basis of psoriasis.

Authors:  Kristine E Nograles; Batya Davidovici; James G Krueger
Journal:  Semin Cutan Med Surg       Date:  2010-03

3.  Different cytokine profiles of skin-derived T cell cultures from patients with atopic dermatitis and psoriasis.

Authors:  Britta C Martel; Beatrice Dyring-Andersen; Lone Skov; Kristian Thestrup-Pedersen; Søren Skov; Kresten Skak; Lars K Poulsen
Journal:  Inflamm Res       Date:  2015-12-31       Impact factor: 4.575

4.  Interleukin 22 signaling promotes cell growth in mantle cell lymphoma.

Authors:  Pascal Gelebart; Zoulika Zak; Jennifer Dien-Bard; Mona Anand; Raymond Lai
Journal:  Transl Oncol       Date:  2011-02-01       Impact factor: 4.243

5.  Pituitary adenylate cyclase-activating peptide and vasoactive intestinal polypeptide bias Langerhans cell Ag presentation toward Th17 cells.

Authors:  Wanhong Ding; Michela Manni; Lori L Stohl; Xi K Zhou; John A Wagner; Richard D Granstein
Journal:  Eur J Immunol       Date:  2012-04       Impact factor: 5.532

6.  Pathways to managing atopic dermatitis: consensus from the experts.

Authors:  Mark G Lebwohl; James Q Del Rosso; William Abramovits; Brian Berman; David E Cohen; Emma Guttman; Anthony J Mancini; Lawrence A Schachner
Journal:  J Clin Aesthet Dermatol       Date:  2013-07

7.  Dysbiosis and Staphylococcus aureus Colonization Drives Inflammation in Atopic Dermatitis.

Authors:  Tetsuro Kobayashi; Martin Glatz; Keisuke Horiuchi; Hiroshi Kawasaki; Haruhiko Akiyama; Daniel H Kaplan; Heidi H Kong; Masayuki Amagai; Keisuke Nagao
Journal:  Immunity       Date:  2015-04-21       Impact factor: 31.745

8.  Cyclosporine A immunosuppression drives catastrophic squamous cell carcinoma through IL-22.

Authors:  Melody Abikhair; Hiroshi Mitsui; Valerie Yanofsky; Nazanin Roudiani; Channa Ovits; Teddy Bryan; Tatiana M Oberyszyn; Kathleen L Tober; Juana Gonzalez; James G Krueger; Diane Felsen; John A Carucci
Journal:  JCI Insight       Date:  2016-06-02

9.  CD8(+) T cells in the lesional skin of atopic dermatitis and psoriasis patients are an important source of IFN-γ, IL-13, IL-17, and IL-22.

Authors:  Dirkjan Hijnen; Edward F Knol; Yoony Y Gent; Barbara Giovannone; Scott J P Beijn; Thomas S Kupper; Carla A F M Bruijnzeel-Koomen; Rachael A Clark
Journal:  J Invest Dermatol       Date:  2012-12-06       Impact factor: 8.551

Review 10.  Tocilizumab-induced psoriasis-like eruption resolved by shortening the dose interval in a patient with rheumatoid arthritis: a case-based review.

Authors:  Michitaro Hayakawa; Keisuke Izumi; Misako Higashida-Konishi; Mari Ushikubo; Masako Tsukamoto; Kumiko Akiya; Kazuhiro Araki; Hisaji Oshima
Journal:  Rheumatol Int       Date:  2018-10-24       Impact factor: 2.631

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.